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Abstract: Background : Although the expression levels of many P450s differ between tumour and corresponding normal tissue, CYP1B1 is one of the few CYP subfamilies which is significantly and consistently overexpressed in tumours.  CYP1B1 has been shown to be active within tumours and is capable of metabolising a structurally diverse range of anticancer drugs. Because of this, and its role in the activation of procarcinogenses is mentioned al rrect format. See e-mail.vant. further studiesreversable resistance, CYP1B1  is seen as an important target for anticancer drug development. Objectives: To synthesise a series of chalcone derivatives based on the chemopreventative agent DMU-135 and investigate  their antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1. Method:  A series of chalcones were synthesised in yields of 43-94% using the Claisen-Schmidt condensation reaction. These were screened using a MTT assay against a panel of breast cancer cell lines which have been characterised for CYP1 expression. Results: A number of derivatives showed promising antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1, while showing significantly lower toxicity towards a non-tumour breast cell line with no CYP expression. Experiments using the CYP1 inhibitors acacetin and α-naphthoflavone provided supporting evidence for the involvement of CYP1 enzymes in the bioactivation of these compounds. Conclusions: Chalcones show promise as anticancer agents with evidence suggesting that CYP1 activation of these compounds may be involved .






Cytochrome P450 (CYP) expression has been studied in a variety of human tumors. It is now recognised that many cancers including those of the breast, bladder, colon, oesophagus, kidney, lung, ovary, prostate, stomach, and soft tissue sarcoma have distinct P450 profiles and overexpress specific P450 sub-families [1, 2]. This overexpression of P450 family members can and does influence the metabolism of anticancer drugs. The therapeutic action of a number of clinically used anticancer agents has been shown retrospectively to involve metabolism by CYPs, and a number of anticancer prodrugs have been designed to be activated by these enzymes [3]. Although the expression levels of many P450s differ between tumour and corresponding normal tissue, CYP1B1 is one of the few CYP subfamilies which is significantly and consistently overexpressed in tumours [4].  CYP1B1 has been shown to be active within tumours and is capable of metabolising a structurally diverse range of anticancer drugs leading to drug resistance in certain cancer cell lines [4]. Because of this, and its role in the activation of procarcinogenses is mentioned al rrect format. See e-mail.vant. further studiesreversable resistance  CYP1B1  is seen as an important target for anticancer drug development, both in terms of developing inhibitors for this enzyme and using it to activate tumour selective prodrugs [5, 6].
Our group has demonstrated that certain naturally occurring methoxylated flavones with good bioavailability but relatively little biological activity are converted by CYP1B1 and CYP1A1 into hydroxylated metabolites with strong antiproliferative activity [7, 8, 9, 10].  This bioactivation was thought to explain the selective action of diosmetin and eupatorin (1a and 2a, Fig.1) against human breast cancer cell lines which express these CYP1 subfamilies [8, 9, 10, 11]. CYP1B1 and CYP1A1 accept a range of flavonoids as substrates and catalyse either 3'-hydroxylation, 4'-O-demethylation, 6-hydroxylation, or 7-O-demethylation [7]. The active metabolite of diosmetin was found to be luteolin (1b, Fig.1) whereas eupatorin was initially converted to cirsiliol (2b, Fig.1), and then by subsequent CYP1 catalysed transformations, into a bioactive polyphenolic metabolite. The activity of both diosmetin and eupatorin in CYP1 expressing cell lines was significantly reduced by the co-application of acacetin, a known CYP1 inhibitor [10, 11] The citrus polymethoxylated flavone nobiletin (3, Fig.1), in addition to showing similar bioactivation to diosmetin and eupatorin in breast cancer cell lines, was also found to induce its own metabolism in these cells via CYP1A1 and CYP1B1 upregulation [11]. Chalcones are precursors in the plant biosynthesis of flavones and are widely distributed in nature. They can be easily synthesised using the Claisen-Schmidt condensation reaction (Scheme 1) [12] and have received considerable recent attention due to their wide range of biological actions, [13, 14, 15, 16] including anticancer activity [17, 18, 19, 20]. Structure-activity studies on methoxylated chalcones have shown that their antiproliferative activity is very much dependent on the presence and relative positions of hydroxyl and methoxy groups within the molecule [21]. We have reported the chemopreventative activity of the chalcone derivative DMU-135 (4, Fig 1.) on ApcMin/+ mouse gastrointestinal adenoma formation. DMU-135 was well tolerated, induced no systemic side-effects and reduced adenoma multiplicity by 46 ± 18.3% compared to controls. We proposed CYP1B1 selective activation of this compound as a mode of action in a similar fashion to methoxylated flavones. We report here our further studies into DMU-135 and its analogues [22].	
2. MATERIALS AND METHODS 
2.1 Chemistry
Reagents were used as received from Sigma-Aldrich Chemical Company (Dorset, UK). 1H-NMR and 13C-NMR spectra were recorded on a Bruker Avance AV400 NMR spectrometer at 30°C. Tetramethylsilane was used as an internal standard for 1H-NMR spectra. Infrared spectra (IR) were recorded on a Perkin-Elmer 298 Spectrophotometer. Solid samples were prepared as KBr discs and liquids as thin films using NaCl plates. Mass spectra were recorded on a Thermo Scientific LTQ Orbitrap XL at the EPSRC UK National Mass Spectrometry Facility at Swansea University. Melting points were determined using a Gallenkamp melting point apparatus and are uncorrected. Thin layer chromatography (TLC) was carried out using Merck aluminium sheet - silica Gel 60F254 coated plates which were visualised under UV light and stained with either iodine, 2,4-dinitrophenylhydrazine, or phosphomolybdic acid. Elemental analyses (CHN) were carried out by Warwick Analytical Services (Coventry, UK) using a CE440 elemental analyser.
2.2 General procedure for the preparation of chalcones
Sodium hydroxide solution (50 % w/v, 5.3 ml, 66.7 mmol) was added to a stirred solution of the acetophenone (6.67 mmol) and aldehyde (6.67 mmol) in methanol (30 ml). The resulting mixture was stirred at room temperature and sequentially monitored by TLC until the reaction was complete. The reaction was quenched with water (30 ml) and extracted with ethyl acetate (3x30 ml). The combined organic extracts were washed with brine (50 ml), dried with anhydrous magnesium sulfate and the solvent removed in vacuo. The crude product was recrystalised from ethanol.
(E)-3-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-prop-2-en-1-one (DMU-102)
Yellow crystals (1.96 g, 89%), TLC: Rf 0.54 (ethyl acetate/ pet. ether 4:6); m.p. 100-101oC (lit 101-103 oC); m/z [FAB+] 329 ([M+H]+, 100%); max (KBr) /cm-1 1653 (C=O); δH (CDCl3) 3.85 (3H, s, OCH3), 3.95 ( 9H, s, 3xOCH3), 6.95 (2H, d, ArH), 7.25 (2H, s, ArH), 7.37 (1H, d, J=17Hz, C=CH), 7.61 (2H, d, ArH) 7.80 (1H, d, J=17Hz, C=CH); C (CDCl3) 55.4, 56.4, 61.0, 106.2, 114.5, 119.5, 127.7, 130.2, 133.9, 142.4, 144.6, 153.2, 157.5, 161.8, 189.3; HRMS found [M+H]+ 329.1387, C18H17O5 requires [M+H]+ 329.1384; Anal. Calcd C19H20O5: C, 69.50; H, 6.14. Found C, 69.25; H, 6.24.
(E)-3-(4-methoxyphenyl)-1-(2,3,4-trimethoxyphenyl)prop-2-en-1-one (DMU 121)
Pale yellow crystals (1.60 g, 73%), TLC: Rf 0.57 (ethyl acetate/ pet. ether 1:1); m.p. 99-100˚C (lit 93-95 oC);10 m/z [FAB] 329 [M+H]+; max (KBr) /cm-1 1650 (C=O); δH (CDCl3) 3.87 (3H, s, OCH3), 3.94 (9H, s, 3x OCH3), 6.75 (1H, d, ArH), 6.90 (2H, d, ArH), 7.35 (1H, d, J=17Hz, C=CH), 7.45 (1H, d, ArH) 7.55 (2H, d, ArH), 7.65 (1H, d, J=17Hz, C=CH); C (CDCl3) 55.4, 56.1, 61.1, 62.1, 77.0, 100.0, 107.3, 114.4, 124.4, 125.7, 127.1, 127.9, 130.1, 142.2, 143.1, 153.6, 156.8, 161.5, 191.0; HRMS found [M+H]+ 329.1386, C19H21O5 requires [M+H]+ 329.1384; Anal. Calcd C19H20O5: C, 69.50; H, 6.14. Found C, 69.39; H, 6.25.
(E)-1-(2,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (DMU-133)
Yellow crystals (1.38 g, 69%), TLC: Rf 0.79 (ethyl acetate/40-60 pet. ether 1:1); m.p. 85-87oC (lit 88-90 oC); m/z [FAB+] 299 ([M+H]+, 100%), max (KBr) /cm-1 1640 (C=O), H (CDCl3) 3.90-3.80 (9H, 3xs, 3xOCH3), 6.50(1H, s, ArH), 6.60 (1H, dd, ArH), 6.90 (2H, d, ArH), 7.40 (1H, d, J=17Hz, C=CH), 7.55 (2H, d, ArH), 7.65 (1H, d, J=17Hz, C=CH), 7.70 (1H, d, ArH); C (CDCl3) 55.5, 55.7, 98.7, 105.1, 114.3, 122.5, 125.0, 128.2, 129.9, 132.7, 142.1, 160.2, 161.2, 163.9, 190.7; HRMS found [M+H]+ 299.1279, C18H19O4 requires [M+H]+ 299.1278; Anal Calcd C18H18O4: C, 72.47; H, 6.08. Found C, 72.20; H, 6.29.
(E)-1-(3, 5-dimethoxyphenyl)-3-(4-methoxyphenyl) prop-2-en-1-one (DMU 120)
Yellow crystals (1.05 g, 53%) TLC: Rf 0.60 (ethyl acetate/pet. ether 1:1); m.p. 94-96oC; m/z [FAB+] 299 ([M+H]+, 100%); max (KBr) /cm-1 1650 (C=O); H (CDCl3) 3.85 (9H, s, OCH3), 6.65 (1H, d, ArH), 6.95 (2H, d, ArH), 7.15 (2H, s, ArH), 7.35 (1H, d, J=15Hz, C=CH), 7.60 (2H, d, ArH), 7.75 (1H, d, J=15Hz, C=CH); C (CDCl3) 55.4; 55.6, 104.8, 106.3, 114.4, 119.8, 127.6, 130.3, 140.5, 144.8, 160.8, 161.7, 190.2; HRMS found [M+H]+ 229.1277, C18H19O4 requires [M+H]+ 299.1278; Anal. Calcd C18H18O4: C, 72.47; H, 6.08. Found C, 72.38; H, 6.27.
(E)-1-(2,5-Dimethoxylphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (DMU-427)
Yellow crystals (1.40 g, 70%), m.p. 96-990C; m/z [FAB] 299 ([M+H]+, 100%); max (KBr) /cm-1 1654 (C=O); H (CDCl3) 3.80 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.87 (3H, s, OCH3), 6.90 (3H, m, ArH), 7.00 (1H, dd, ArH), 7.15 (1H, s, ArH), 7.28 (1H, d, J=17Hz, C=CH), 7.52 (2H, d, ArH), 7.50 (1H, d, J=17Hz, C=CH); c (CDCl3) 55.4, 55.8, 56.5, 113.4, 114.4, 118.7, 124.7, 127.8, 130.0, 143.5, 152.4, 153.6, 161.5, 192.6 ; HRMS found [M+H]+ 299.1281, C18H19O4 requires [M+H]+ 299.1278.
 (E)-1-(4-methoxylphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (DMU-470)
Yellow crystals (1.52 g, 85%), ); m.p.99-101oC; m/z [FAB] (269 [M+H]+, 100%); max (KBr) /cm-1 1652 (C=O); H (CDCl3) 3.80 (3H, s, OCH3), 3.85 (3H, s, OCH3), 6.85 (2H, d, ArH), 7.00(2H, m, ArH), 7.20 (1H, d, J=17Hz, C=CH), 7.40 (1H, m, ArH), 7.45 (1H, m, ArH), 7.50 (2H, d, J=17Hz, C=CH), 7.55 (1H, d, ArH); c (CDCl3) 55.4, 55.8, 111.7, 114.4, 120.9, 124.9, 127.7, 129.5, 130.2, 132.7, 143.4, 158.0, 161.5, 193.1; HRMS found [M+H]+ 269.1169, C17H17O3 requires [M+H]+ 269.1172.
(E)-3-(4-Methoxyphenyl)-1-phenylprop-2-en-1-one (DMU-105)
Yellow crystals (1.41 g, 89%), TLC: Rf 0.36 (ethyl acetate/ 40-60 pet. ether 1:1); m.p. 56-58oC, m/z [FAB] 239 ([M+H]+, 100%); max (KBr) /cm-1 1650 (C=O); H (CDCl3) 3.90 (3H, s, OCH3), 6.95 (2H, d, ArH), 7.40(1H, d, J=17Hz, C=CH), 7.45 (3H, m, ArH), 7.60 (2H, d, ArH), 7.75 (1H, d, J=17Hz, C=CH), 8.00 (2H, dd, ArH); C (CDCl3) 55.5, 114.5, 119.9, 127.7, 128.5, 128.6, 130.2, 132.6, 138.6, 144.7, 158.1, 161.8; HRMS found [M+H]+ 239.1066, C16H14O2 requires [M+H]+ 239.1067.
 (E)-1-(4-methoxyphenyl)-3-(phenyl) prop-2-en-1-one (DMU-1119)
Yellow crystals (0.94 g, 59%) , TLC: Rf 0.42 (ethyl acetate/pet. ether 2:8); m.p. 78-80 oC (lit 79 oC); m/z [FAB] 239 ([M+H]+, 100%); max (KBr) /cm-1 1659 (C=O); H (CDCl3) 3.85 (3H, s, OCH3), 6.95 (2H, d, ArH), 7.40 (3H, m, ArH), 7.55 (1H, d, J=15Hz, C=CH ), 7.60 (2H, m, ArH), 7.80 (1H, d, J=15Hz, C=CH), 8.10 (2H, d, ArH); c (CDCl3) 55.5, 113.9, 121.9, 128.4, 129.0, 130.4, 130.9, 131.1, 135.1, 141.2, 144.0, 163.5, 188.7; HRMS found [M+H]+ 239.1068, C16H15O2 requires [M+H]+ 239.1067.
(E)-1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (DMU-1113)
Yellow crystals (1.24 g, 57%), m.p.133-134oC; m/z [FAB] 329 ([M+H] +, 100%); max (KBr) /cm-1 1651 (C=O); H (CDCl3) 3.85 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.93 (3H, s, OCH3), 6.85 (2H, s, ArH), 6.95 (2H, d, ArH), 7.45 (1H, d, J=19Hz, C=CH), 7.71 (1H, d, J=19Hz, C=CH), 7.55 (1H, d, ArH), 8.05 (1H, d, ArH); c (CDCl3) 55.5, 56.2, 61.0, 105.5, 113.8, 121.2, 130.6, 130.8, 131.1, 140.2, 141.2, 153.4, 163.4, 188.6; HRMS found [M+H]+ 329.1388, C19H21O5 requires [M+H]+ 399.1384.
(E)-1-(2,4-dimethoxyphenyl)-3-(4-ethoxyphenyl)prop-2-en-1-one (DMU-1122)
Yellow crystals (1.40 g, 67%), TLC:Rf 0.8 (ethyl acetate/pet. ether 3:7); m.p. 98-100oC; m/z [FAB+] 313 ([M+H]+, 100%); max (KBr) /cm-1 1650 (C=O); H (CDCl3) 1.40 (3H, t, CH3), 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 4.05 (2H, m, CH2O), 6.50 (1H, s, ArH), 6.65 (1H, d, ArH), 6.90 (2H, d, ArH), 7.40(1H, d, J=16Hz, C=CH), 7.55(2H, d, ArH), 7.65(1H, d, J=16Hz, C=CH), 7.75(1H, d, ArH); C (CDCl3) 14.7, 55.5, 55.7, 63.6, 98.6, 105.1, 114.8, 122.4, 124.9, 127.9, 130.0, 132.7, 142.2, 160.3, 160.7, 164.0, 190.7; HRMS found [M+H]+ 313.1439, C19H21O4 requires [M+H]+ 313.1434.
(E)-3-(4-ethoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (DMU-5505)
Pale yellow crystals (1.70 g, 74%), TLC: Rf 0.52 (ethyl acetate/petroleum ether 4:6); m.p. 120-121oC;  m/z [MALDI] 343 ([M+H]+, 100%); max (KBr) /cm-1 1656 (C=O); H (CDCl3) 3.91 (3H, s, OCH3), 3.92 (3H, s, OCH3), 3.94, (3H, s, OCH3), 4.1 (2H, q, OCH2), 6.75 (1H, d, ArH), 6.90 (2H, d, ArH), 7.40 (1H, d, J=17Hz, C=CH), 7.50 (1H, d, ArH), 7.60 (2H, d, ArH), 7.70 (1H, d, J=17Hz, C=CH); C (CDCl3) 14.7, 50.6, 56.1, 61.1, 62.1, 63.6, 107.3, 114.8, 124.1, 125.7, 127.0, 130.2, 143.5, 153.6, 156.8, 160.9, 191.4; HRMS found [M+H]+ 343.1543, C20H23O5 requires [M+H]+ 343.1540.
(E)-1-(2,4-Dimethoxyphenyl)-3-(4-propoxyphenyl)prop-2-en-1-one (DMU-408)
Yellow crystals (1.10 g, 51%), TLC: Rf 0.54 (ethyl acetate/40-60 pet. ether 4:6); m.p. 160-161oC; m/z [MALDI] 326 ([M]+, 100%); max (KBr) /cm-1 1598 (C=O); H (CDCl3) 1.0 (3H, t, CH3), 1.8 (2H, m, CH2), 3.95 (3H, s, OCH3), 4.0 (3H, s, OCH3), 4.05 (2H, t, OCH2), 6.50 (1H, s, ArH), 6.60 (1H, d, ArH), 6.95 (2H, d, ArH), 7.40 (1H, d, J=13Hz, C=CH), 7.55 (2H, d, 2H), 7.70 (1H, d, J=13Hz, C=CH), 7.85 (1H, d, ArH); C (CDCl3) 10.4, 22.5, 55.9, 56.0, 69.6, 110.0, 114.9, 115.1, 119.1, 122.8, 127.6, 129.8, 130.1, 143.8, 153.1, 161.1, 188.5; HRMS found [M+H]+ 327.1591, C20H23O4 requires [M+H]+ 327.1591; Anal Calcd C20H22O4: C, 73.62; H, 6.75. Found C, 73.48; H, 6.81.
 (E)-3-(4-propoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (DMU-191)
Yellow crystals (1.9 g, 79%), TLC:Rf 0.60 (ethyl acetate/petroleum ether 4:6); m.p. 115-118oC; m/z [FAB] 357 ([M+H]+, 100%); max (KBr) /cm-1 1653 (C=O); H (CDCl3) 1.04 (3H, t, CH3), 1.80 (2H, m, CH2), 3.80 (9H, s, 3xOCH3), 3.95 (2H, m, OCH2), 6.72 (1H, d, ArH), 6.88 (2H, d, ArH), 7.34 (1H, d, J=16Hz, C=CH), 7.44, (1H, d, ArH), 7.54 (2H, d, ArH), 7.64 (1H, d, J=16Hz, C=CH); C (CDCl3) 56.3, 60.9, 69.7, 106.1, 114.9, 119.3, 127.4,  130.1, 133.8, 142.4, 144.7, 153.1, 156.9, 161.3, 189.3; HRMS found [M+H]+ 357.1699, C21H25O5 requires [M+H]+ 357.1697; Anal. Calcd C21H24O5.0.5H2O: C, 68.96; H, 6.84. Found C, 69.07; H, 6.86.
 (E)-3-(4-butoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2- en-1-one (DMU-192)
Yellow crystals (1.7 g, 69%), m.p. 125-128oC; m/z [FAB] 371 ([M+H]+, 100%); max (KBr) /cm-1 1650 (C=O); H (CDCl3) 7.80 (1H, d, J=17Hz, C=CH), 7.60 (2H, d, ArH), 7.38 (1H, d, J=17Hz, C=CH), 7.28 (2H, d, ArH), 6.95 (2H, d, ArH), 4.05 (2H, t, CH2O), 3.95 (6H, s, 2 x OCH3), 3.90(3H, s, OCH3), 1.80 (2H, p, CH2CH2O), 1.55 (2H, m, CH2CH2CH2O), 1.00 (3H, t, CH2CH3); c (CDCl3) 13.9, 19.2, 31.2, 56.4, 61.0, 67.9, 100.0, 105.9, 114.9, 119.2, 127.3, 130.3, 133.9, 141.2, 142.2, 144.8, 153.1, 161,4, 174.4, 189.3; HRMS found [M+H]+ 371.1855, C22H27O5 requires [M+H]+ 371.1853.
(E)-3-(3,4-dimethoxyphenyl) - 1-(3,4,5-trimethoxyphenyl)- prop-2-en-1-one(DMU-104)
Yellow crystals (1.58 g, 66%), TLC: Rf 0.54 (ethyl acetate/pet. ether 4:6); m.p. 131-132oC (lit 127-129 oC); m/z [FAB] 359 ([M+H]+, 100%);  max (KBr) /cm-1 1650 (C=O); H (CDCl3) 3.90 (15H, s, 5xOCH3), 6.90 (1H, s, ArH), 7.10(1H, s, ArH) 7.3 (3H, m, ArH), 7.50 (1H, d, J=16Hz, C=CH) , 7.80 (1H, d, J=16Hz, C=CH); C (CDCl3) 52.5, 53.0, 57.4, 102.7, 107.1, 107.7, 116.4, 119.3, 124.4, 130.3, 139.0, 141.4, 145.8, 148.0, 149.6 158.2, 185.9; HRMS found [M+H]+ 359.1493, C20H23O6 requires [M+H]+ 359.1489; Anal. Calcd C20H22O6.0.5H2O: C, 65.40; H, 6.27. Found C, 65.82; H, 6.28.
(E)-1-(2,4-Dimethoxyphenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one (DMU-2201)
Off-white crystals (1.50 g, 68%), TLC: Rf 0.59 (ethyl acetate/40-60 pet. ether 3:6); m.p. 109-112oC; m/z [FAB +] 329 ([M+H]+ 100%), max (KBr) /cm-1 1653 (C=O); H (CDCl3) 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 4.00 (6H, s, OCH3), 6.50 (1H, s, ArH), 6.55 (1H, d, ArH), 6.90 (1H, d, ArH), 7.10 (1H, s, ArH), 7.20 (1H, d, ArH), 7.35 (1H, d, J=16Hz, C=CH), 7.60 (1H, d, J=16Hz, C=CH), 7.70 (1H, d, ArH), C (CDCl3) 55.5, 55.7, 55.8, 55.9, 98.7, 105.1, 110.3, 111.2, 122.4, 122.6, 125.3, 128.4, 132.6, 142.3, 149.4, 150,9, 160,2, 163.9, 190.6; HRMS found [M+H]+ 329.1378, C19H21O5 requires [M+H]+ 329.1384.
(E)-1-(3,4-dimethoxyphenyl)-3-(3, 4-dimethoxyphenyl) prop-2-en-1-one (DMU-2210)
Yellow crystals (1.35 g, 62%), TLC: Rf 0.42 (ethyl acetate/pet. ether 1:9); m.p. 100-102oC (lit 104-106 oC);  m/z [MALDI] 329 ([M+H]+, 100%); max (KBr) /cm-1 1651 (C=O); H (CDCl3) 3.90 (3H, s, OCH3), 3.95 (3H, s, OCH3), 4.00 (6H, s, OCH3), 6.87-6.94 (2H, m, ArH), 7.17 (1H, s, ArH), 7.24 (1H, s, ArH), 7.42 (1H, d, J=16Hz, C=CH), 7.62 (1H, s, ArH), 7.68 (1H, d, ArH), 7.77 (1H, d, J=16Hz, C=CH); C (CDCl3) 55.9, 56.0, 109.9, 110.2, 110.3, 110.8, 110.9, 111.1, 119.7, 122.8, 128.1, 131.6, 144.1, 149.2, 151.3, 153.1, 188.6; HRMS found [M+H]+ 329.1385, C19H21O5 requires [M+H]+ 329.1384; Anal. Calcd C19H20O5: C, 69.50; H, 6.14. Found C, 69.54; H, 6.42.
(E)-3-(2,4-dimethoxyphenyl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (DMU-132)
Yellow crystals (1.67 g, 70%), TLC:Rf 0.42 (ethyl acetate/pet. ether 1:9); m.p. 129-131oC; m/z [MALDI] 359 ([M+H]+, 100%); max (KBr) /cm-1 1651 (C=O), H (CDCl3) 3.83 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.90-3.95(9H, 2xs, 3x OCH3), 6.50 (1H, s, ArH), 6.60 (1H, dd, ArH), 7.20 (2H, s, ArH), 7.40 (1H, d, J=15Hz, C=CH), 7.55 (1H, d, ArH), 8.00 (1H, d, J=15Hz, C=CH); C (CDCl3) 55.5, 56.4, 60.9, 98.5, 105.5, 106.2, 117.3, 120.4, 130.8, 134.2, 140.5, 142.1, 153.1, 160.4, 163.1, 190.2 (C=O); HRMS found [M+H]+ 359.1493, C20H23O6 requires [M+H]+ 359.1489; Anal. Calcd C20H22O6.0.5H2O: C, 65.38; H, 6.31. Found C, 65.34; H, 6.40.
(E)-1-(2,4-Dimethoxyphenyl)-3-(2,4-dimethoxyphenyl)prop-2-en-1-one (DMU-2207)
Yellow crystals (1.60 g, 73%), TLC: Rf 0.48 (ethyl acetate/40-60 pet. ether 1:9); m.p. 122-123oC; m/z [MALDI] 328 ([M]+, 100%); max (KBr) /cm-1 1643 (C=O); H (CDCl3) 3.80 (3H, s, OCH3), 3.85 (6H, s, OCH3), 3.90 (3H, s, OCH3), 6.55 (1H, s, ArH), 6.60-6.70 (3H, m, ArH), 7.45 (1H, d, J=16Hz, C=CH), 7.60 (1H, d, ArH), 7.80 (1H, d, ArH), 8.00 (1H, d, J=16Hz, C=CH); C (CDCl3) 55.4, 55.5, 55.7, 98.4, 98.8, 105.1, 105.4, 117.6, 122.9, 125.5, 130.2, 132.6, 137.9, 160.2, 162.7, 163.7, 191.3; HRMS found [M+H]+ 329.1386, C19H21O5 requires [M+H]+ 329.1384.
 (E)-3-(3,4-Methylenedioxyphenyl)-1-(3,4,5-trimethoxy-phenyl) -prop-2-en-1-one (DMU-135)
Yellow crystals (1.75 g, 77%), TLC: Rf 0.72 (ethyl acetate/40-60 pet. ether 2:8); m.p. 135-136oC (lit 133-135 oC); m/z [FAB] 343 ([M+H]+, 100%); max (KBr) /cm-1 1650 (C=O); H (CDCl3) 3.92 (3H, s, OCH3), 3.93 (6H, s, OCH3), 6.01 (2H, s, OCH2O), 6.83 (1H, s, ArH), 7.11 (1H, d, ArH), 7.15 (1H, d, ArH), 7.25 (2H, s, ArH), 7.30 (1H, d, J=16Hz, C=CH), 7.72 (1H, d, J=16Hz, C=CH); C (CDCl3), 56.4, 61.0, 101.7, 106.1, 106.7, 108.7, 119.8, 125.3, 133.7, 142.4, 144.6, 148.4, 150.0, 153.2, 189.1; HRMS found [M+H]+ 343.1176, C19H19O6 requires [M+H]+ 343.1176; Anal Calcd for C19H18O6 : C, 66.66; H, 5.30. Found C, 66.49; H, 5.44.
(E)-3-(3,4-Methylenedioxyphenyl)-1-(2,3,4-trimethoxy-phenyl)prop-2-en-1-one (DMU-419)
Yellow crystals (1.71 g, 75%), TLC: Rf 0.71 (ethyl acetate/40-60 pet. ether 3:7); m.p. 70-71oC; m/z [FAB] 343 ([M+H]+, 100%); max (KBr) /cm-1 1690 (C=O); H (CDCl3) 3.90 (9H, s, OCH3), 6.00 (2H, s, OCH2O), 6.74 (1H, d, ArH), 6.82 (1H, d, ArH), 7.08 (1H, d, ArH), 7.18 (1H, s, ArH), 7.33 (1H, d, J=16Hz, C=CH), 7.46 (1H, 2, ArH), 7.59 (1H, d, J=16Hz, C=CH), C (CDCl3) 56.1, 61.0, 62.1, 101.5,106.7, 107.4, 108.6, 124.8, 124.9, 125.7, 127.0, 142.2, 142.9, 148.4, 149.6, 153.7, 156.9, 190.7; HRMS found [M+H]+ 343.1178, C19H19O6 requires [M+H]+ 343.1176; Anal Calcd C19H18O6: C, 66.66; H, 5.30. Found C, 66.56; H, 5.43.
(E)-1-(2,4-Dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)-prop-2-en-1-one (DMU-407)
Yellow crystals (1.77 g, 85%), TLC: Rf 0.71 (ethyl acetate/40-60 pet. ether 3:7); m.p. 124-127oC (lit 123-125oC); m/z [FAB] 313 ([M+H]+, 100%), max (KBr) /cm-1 1658 (C=O); H (CDCl3) 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 6.00 (2H, s, OCH2O), 6.50 (1H, d, ArH), 6.55 (1H,dd, ArH), 6.80 (1H, d, ArH), 7.05 (1H,dd, ArH), 7.10 (1H, d, ArH), 7.30 (1H, d, J=16Hz, C=CH), 7.60 (1H, d, J=16Hz, C=CH), 7.75 (1H, d, ArH); C (CDCl3) 55.9, 56.1, 99.1, 101.8, 105.6, 107.0, 108.9, 122.8, 125.1, 125.8, 139.3, 133.1, 142.3, 148.6, 149.7, 160.7, 164.4, 190.7; HRMS found [M+H]+ 313.1071, C18H17O5 requires [M+H]+ 313.1071; Anal Calcd C18H16O5: C, 69.23; H, 5.13. Found C, 68.97; H, 5.26.
(E)-1-(3,4-Dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)- prop-2-en-1-one (DMU-160) 
Yellow crystals (1.96 g, 94%), TLC: Rf 0.71 (ethyl acetate/40-60 pet. ether 3:7); m.p. 144-145oC; m/z [FAB] 313 ([M+H, 100%]; max (KBr) /cm-1 1653 (C=O); H (CDCl3) 3.95 (6H, s, 2x OCH3), 6.00 (2H, s, OCH2O), 6.85 (1H, d, ArH), 6.95 (1H, d, ArH), 7.12 (1H, d, ArH), 7.18 (1H, s, ArH), 7.38 (1H, d, J=15Hz, C=CH), 7.62 (1H, s, ArH), 7.66 (1H, d, ArH), 7.40 (1H, d, J=15Hz, C=CH); C (CDCl3) 56.4 (OCH3), 56.5 (OCH3), 102.0 (OCH2O), 107.0, 109.0, 110.4, 111.3, 120.2, 123.2, 125.3, 130.0, 131.9, 144.2, 148.8, 149.7, 150.1, 153.7, 188.8; HRMS found [M+H]+ 313.1073, C18H17O5 requires [M+H]+ 313.1071.
 
(E)-1-(3,5-Dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)-prop-2-en-1-one (DMU-403)
Yellow crystals (1.19 g, 56%), TLC: Rf 0.71 (ethyl acetate/40-60 pet. ether  3:7); m.p. 104-105oC; m/z [FAB] 313 ([M+H]+, 100%); max (KBr) /cm-1 1668 (C=O); H (CDCl3) 3.95 (6H, s, OCH3), 6.00 (2H, s, OCH2O), 6.75 (1H, s, ArH), 6.85 (1H, d, ArH), 7.05-7.15 (4H, m, ArH), 7.35 (1H, d, J=17Hz, C=CH), 7.85 (1H, d, J=17Hz, C=CH); C (CDCl3) 55.6, 101.6, 104.8, 106.3, 106.7, 108.6, 120.1, 125.2, 129.4, 140.4, 144.7, 148.4, 149.94, 160.9, 189.9; HRMS found [M+H]+ 313.1073, C18H17O5 requires [M+H]+ 313.1071; Anal. Calcd C18H16O5: C, 69.23; H, 5.19. Found C, 69.15; H, 5.18.
 (E)-1-(2,5-Dimethoxyphenyl)-3-(3,4-methylenedioxyphenyl)-prop-2- en-1-one (DMU-423) 
Yellow crystals (1.07 g, 51%), TLC: Rf 0.55 (ethyl acetate/40-60 pet. ether 2:8); m.p. 110-114oC; m/z [FAB] 313 ([M+H]+, 50%); max (KBr) /cm-1 1653 (C=O); H (CDCl3) 3.80 (3H, s, OCH3), 3.85 (3H, s, OCH3), 6.00 (2H, s, OCH2O), 6.80 (1H, s, ArH), 6.94 (1H, s, ArH), 7.01 (1H, d, ArH), 7.03 (1H, d, ArH), 7.11 (1H, d, ArH), 7.22(1H, d, ArH), 7.55(1H, d, J=14Hz, C=CH), 7.65(1H, d, J=14Hz, C=CH); C (CDCl3) 55.9, 56.5, 101.6, 108.6, 108.7, 113.4, 114.4, 123.8, 125.1, 129.3, 142.8, 148.3, 152.5, 153.6, 192.3; HRMS found [M+H]+ 313.1070, C18H17O5 requires [M+H]+ 313.1071; Anal Calcd C18H16O5; C, 69.23; H, 5.13. Found C, 69.25; H, 4.88.
(E)-1-(2-Methoxyphenyl)-3-(3,4-methylenedioxyphenyl)prop-2-en-1-one (DMU-2265)
Yellow crystals (1.59 g, 85%), TLC: Rf 0.54 (ethyl acetate/40-60 pet. ether 4:6); m.p. 120-123oC; m/z [FAB] 283 ([M+H]+, 100%); max (KBr) /cm-1 1651 (C=O); H (CDCl3) 3.90 (3H, s, OCH3), 6.0 (2H, s, OCH2O), 6.80 (1H, d, ArH), 6.97-7.07 (3H, m, ArH), 7.09 (1H, s, ArH), 7.20 (1H, d, J=17Hz, C=CH), 7.42-7.48 (1H, m, ArH), 7.53 (1H, d, J=17Hz, C=CH), 7.60 (1H, d, ArH); C (CDCl3), 56.2, 101.9, 107.1, 108.9, 112.1, 121.1, 125.4, 125.7, 129.7, 129.9, 130.6, 133.8, 138.5, 143.6, 148.7, 158. 4, 193.3; HRMS found [M+H]+ 383.0962, C17H15O4 requires [M+H]+ 383.0965.
 (E)-1-(3-methoxyphenyl)-3-(3,4-methylenedioxyphenyl)prop-2- en-1-one (DMU-416)
Yellow crystals, (0.8 g, 43%), TLC: Rf 0.60 (ethyl acetate/pet. ether 4:6); m.p. 81-82oC; m/z [FAB] 283 ([M+H]+, 100%); max (KBr) /cm-1 1659 (C=O); H (CDCl3) 3.79 (3H, s, OCH3), 6.50 (2H, s, OCH2O), 6.85 (1H, d, ArH), 7.10 (3H, t, ArH), 7.31 (1H,d, J=16Hz, C=CH), 7.41 (1H, d, ArH), 7.55 (2H, m, ArH), 7.75 (1H, d, J=16Hz, C=CH); C (CDCl3) 56.2, 101.9, 107.1, 109.0, 112.1, 121.1, 125.4, 129.7, 130.6, 133.1, 138.5, 143.6, 148.7, 150.1, 158.4, 193.3; HRMS found [M+H]+ 283.0965, C17H15O4 requires [M+H]+ 283.0965; Anal. Calcd C17H14O4; C, 72.33; H, 5.00. Found C, 72.24; H, 5.02.
(E)-1-(4-Methoxyphenyl)-3-(3,4-methylenedioxyphenyl)prop-2-en-1-one (DMU-2267) 
Yellow crystals (1.48 g, 79%), TLC: Rf 0.49 (ethyl acetate/40-60 pet. ether 3:7); m.p. 126-129oC (lit 127oC); m/z [FAB] 282 ([M+H]+, 100%); max (KBr) /cm-1 1651 (C=O); H (CDCl3) 3.90 (3H, s, OCH3), 6.00 (2H, s, OCH2O), 6.85 (1H, d, ArH), 6.95 (2H, d, ArH), 7.10 (1H, d, ArH), 7.15 (1H, s, ArH), 7.45 (1H, d, J=15Hz, C=CH), 7.70 (1H, d, J=15Hz, C=CH), 8.00 (2H, d, ArH); C (CDCl3), 55.8, 101.9, 109.0, 114.2, 120.4, 125.3, 129.9, 131.1, 131.7, 138.5, 144.4, 148.8, 150.1, 160.8, 163.7, 188.9; HRMS found [M+H]+ 283.0964, C17H15O4 requires [M+H]+ 283.0965.
 (E)-3-(3,4-Methylenedioxyphenyl)-1-phenylprop-2-en-1-one (DMU-411) 
Yellow crystals (1.07 g, 64%), TLC: Rf 0.65 (ethyl acetate/40-60 pet. ether 4:6); m.p. 108-110oC (lit 109oC);16 m/z [FAB+] 253 ([M+H]+ 100%); max (KBr) /cm-1 1659 (C=O); H (CDCl3) 6.0 (2H, s, OCH2O), 6.85 (1H, d, ArH), 7.12 (2H, d, ArH), 7.35 (1H, d, J=16Hz, C=CH), 7.55 (3H, m, ArH), 7.75 (1H, d, J=16Hz, C=CH), 7.98 (2H, d, ArH); C (CDCl3) 101.6, 106.6, 108.7, 120.1, 125.2, 128.5, 129.3, 138.4, 144.6, 148.4, 149.9, 190.3; HRMS found [M+H]+ 253.0858, C16H13O3 requires [M+H]+ 253.0858; Anal Calcd C16H12O3 C, 76.18; H, 4.79. Found C, 75.89; H, 4.98.
 (E)-3-(2,4-Dimethoxyphenyl)-1-(3,4-methylenedioxyphenyl)-prop-2-en-1-one (DMU-1103)
Yellow crystals (1.57 g, 75%), TLC: Rf 0.73 (ethyl acetate/40-60 pet. ether 2:8); m.p. 150-156oC; m/z [FAB ] 313 ([M+H]+, 100%); max (KBr) /cm-1 1650 (C=O); H (CDCl3) 3.90 (3H, s, OCH3), 3.80 (3H, s, OCH3), 6.00 (2H, s, OCH2O), 6.45 (1H, s, ArH), 6.60 (1H, d, ArH), 6.90 (1H, d, J=16Hz, C=CH), 7.10 (1H, d, ArH), 7.60 (1H, d, J=16Hz, C=CH), 7.70 (1H, d, ArH), 8.00 (2H, d, ArH); C (CDCl3) 55.6, 98.4, 101.8, 105.4, 107.8, 108.5, 117.2, 120.0, 124.4, 131.0, 133.0, 140.0, 148.1, 151.3, 160.4, 162.9, 188.9; HRMS found [M+H]+ 313.1074, C18H17O5 requires [M+H]+ 313.1071.
 (E)-3-(2,5-Dimethoxyphenyl)-1-(3,4-methylenedioxyphenyl)-prop-2-en-1-one (DMU-1144)
Yellow crystals (1.40 g, 67%), TLC: Rf 0.57 (ethyl acetate/40-60 pet. ether 2:8); m.p. 99-100oC (lit 94-96oC); m/z [FAB ] 313 ([M+H]+, 100%); max (KBr) /cm-1 1650 (C=O); H (CDCl3) 3.80 (3H, s, OCH3), 3.87 (3H, s, OCH3), 6.05, (2H, s, OCH2O), 6.82 (1H, s, ArH), 6.85 (1H, s, ArH), 6.86 (1H, d, ArH), 7.15 (1H, d, J=15Hz, C=CH), 7.53 (1H, d, ArH), 7.62 (1H, d, ArH), 8.02 (1H, s, J=15Hz, C=CH), 8.05 (1H, s, ArH); C (CDCl3) 55.8, 56.1, 101.9, 107.9, 108.4, 112.4, 113.7, 117.0, 122.6, 124.5, 133.1, 139.5, 148.2, 151.5, 153.2, 158.8, 189.1; HRMS found [M+H]+ 313.1072, C18H17O5 requires [M+H]+ 313.1071. 
 (E)-1-(3,4-methylenedioxyphenyl)-3-(2,3,4-trimethoxy-phenyl)prop-2-en-1-one (DMU 1112)
Yellow crystals (1.52 g, 67%) m.p. 106-109oC; m/z [FAB] 343 ([M+H]+, 100%); max (KBr) /cm-1 1656 (C=O); H (CDCl3) 3.86 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.95 (3H, s, OCH3), 6.05(2H, s, OCH2O), 6.71 (1H, d, ArH), 6.85 (1H, d, ArH), 7.38 (1H, d, ArH), 7.50 (1H, s, ArH), 7.52 (1H, d, J=18Hz, C=CH), 7.65 (1H, dd, ArH), 7.98 (1H, d, J=18Hz, C=CH); c (CDCl3) 56.1, 60.9, 61.4, 101.8, 107.6, 107.8, 108.4, 120.9, 122.0, 123.8, 124.5, 133.3, 139.5, 142.4, 148.2, 151.5, 153.7, 155.7, 188.6; HRMS found [M+H]+ 343.1179, C19H19O6 requires [M+H]+ 343.1176.
(E)-1-(2-Chlorophenyl)-3-(3,4-methylenedioxyphenyl)prop-2-en-1-one (DMU-2219)
Yellow crystals (1.52 g, 80%), TLC: Rf 0.43 (ethyl acetate/40-60 pet. ether 2:8); m.p. 110-111oC; m/z [FAB] 287 ([M+H]+, 100%); max (KBr) /cm-1 1654 (C=O); H (CDCl3) 6.05 (2H, s, OCH2O), 6.95 (1H, s, ArH), 7.15 (1H, d, J=17Hz, C=CH), 7.24 (1H, d, Ar-H), 7.34 (1H, d, J=17Hz, C=CH), 7.44-7.50 (2H, m, Ar-H), 7.51-7.60 (3H, m, Ar-H), C (CDCl3), 101.7, 106.8, 108.7, 124.4 125.5, 126.8, 128.9, 129.3, 131.3, 139.3, 146.2, 148.5, 150.3, 192.7; HRMS found [M+H]+ 287.0474, C16H12O335Cl requires [M+H]+ 287.0469.
 (E)-1-(2,4-Dichlororyphenyl)-3-(3,4-methylenedioxyphenyl)-
prop-2-en-1-one (DMU-2263)
Yellow crystals (1.81 g, 85%), TLC: Rf 0.61 (ethyl acetate/40-60 pet. ether 2:8); m.p. 109-110oC; m/z [FAB] 321 ([M+H]+, 100%); max (KBr) /cm-1 1651 (C=O); H (CDCl3) 6.02 (2H, s, OCH2O), 6.82 (1H, d, J=16Hz, C=CH), 6.94 (1H, d, J=16Hz, C=CH), 7.04 (1H, d, ArH), 7.08 (1H, s, ArH), 7.32-7.37 (1H, m, ArH), 7.39-7.44 (2H, m, ArH) 7.48 (1H, s, ArH); C (CDCl3) 101.7, 106.7, 108.7, 124.0, 125.6, 127.2, 128.7, 130.1, 132.3, 132.3, 136.7, 137.7, 146.3, 148.5, 150.4, 192.3; HRMS found [M+H]+ 321.0085, C16H11O335Cl2 requires [M+H]+ 321.0080.
 (E)-1-(2,4-Dimethoxyphenyl)-3-(3,4-ethylenedioxyphenyl)-
prop-2-en-1-one (DMU-1133)
Yellow crystals (1.96 g, 90%), TLC: Rf 0.42 (ethyl acetate/40-60 pet. ether 2:8); m.p. 99-101oC; m/z [FAB] 327 ([M+H] +, 100%); max (KBr) /cm-1 1655 (C=O); H (CDCl3) 3.95 (6H, s, 2 x OCH3),  4.28 (4H, m, OCH2CH2O), 6.90 (1H, d, ArH), 6.92 (1H, d, ArH), 7.15 (1H, dd, ArH), 7.18 (1H, d, ArH), 7.40 (1H, d, J=16Hz, C=CH ), 7.60 (1H, d, ArH), 7.65 (1H, dd, ArH), 7.70 (1H, d, J=16Hz, C=CH); C (CDCl3) 56.4, 61.0, 64.3, 106.1, 116.9, 117.8, 120.0, 122.8, 128.6, 133.8, 142.4, 144.5, 146.0, 153.2, 189.2; HRMS found [M+H]+ 327.1227, C19H19O5 requires [M+H]+ 327.1227.
2.3 MTT cytotoxicity assay 
Cells were purchased from the American Type Culture Collection (Virginia, USA). MCF-7 cells were grown in RPMI-1640 medium with phenol red and 10% (v/v) heat inactivated (heated to 56°C for 45 mins) foetal calf serum. MDA-468 cells were grown in RPMI-1640 medium with 10% (v/v) heat inactivated foetal calf serum and L-glutamine (2 mM) without phenol red. MCF-10A cells were grown in Dulbecco’s modified Eagle’s medium/ Ham’s F-12 medium (1:1) with 5% (v/v) heat inactivated foetal calf serum, epidermal growth factor (20 ng/ml), insulin (10 µg/ml) and hydrocortisone (500 ng/ml). Cells were maintained at 37°C, 5% CO2 / 95% air with 100% humidity and passaged every 2-3 days using trypsin EDTA solution (0.25% w/v). Adhered cells at sub confluence were harvested for experimental use. The medium was aspirated and discarded and trypsin-EDTA solution (1% w/v, 1 ml) was added to the cells. After 30 seconds this was aspirated and immediately replaced by a further 1 ml of trypsin-EDTA solution. The cells were incubated at 37°C for approximately 5 mins or until the cells were visibly non-adherent. The resultant cell suspension was placed in a 25 ml sterile universal container with 10 ml of fresh medium followed by centrifugation (3 min, 3000 rpm and 4°C). Old medium was aspirated and replaced with 10 ml of fresh medium. To determine the density of cells in suspension, an aliquot (100 µl) was added to a trypan-blue solution (0.4% w/v, 100 µl) and the number of viable cells determined using a Neubauer haemocytometer. The cell suspension was diluted with relevant medium to give a cell count of 2x103 cells per ml. Aliquots (100 µl) were dispensed into sterile 96-well microtitre flat-bottomed plates. For the MDA-468 and MCF-10A cell lines the plates were incubated at 37°C, 5% CO2/95% air with 100% humidity for 24 hours prior to the addition of test compounds. For MCF-7 cells, after allowing approximately 4 h for cells to adhere, 100 µl of medium containing TCDD (from 100 mM stock in DMSO) or medium with 0.2% (v/v) DMSO was added to give a final concentration of 10 nM TCDD and 0.1% (v/v) DMSO. After 24 h the medium was aspirated and replaced with fresh medium (100µl) before the addition of test compounds. Test compounds were added within 30 mins into the wells from a 100 mM stock solution in DMSO and serially diluted to give final concentrations of 100, 30, 10, 3, 1, 0.1, 0.93, 0.01, 0.003, 0.001 and 0.0003 µM. The final concentration of DMSO did not exceed 0.1% v/v in each well. The cells were allowed to grow for 96 h at 5%, CO2, 37°C to give 80-90% confluence in the control wells after which 50 µl of MTT (3-[4, 5 dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide 2mgml-1) in sterile phosphate buffer was added to each well and the plates were further incubated for 2 h. All medium was aspirated and the formazan precipitate generated by viable cells was solubilised by 150 µl of DMSO. All the plates were vortexed and the absorbance at 540nm was determined using a Molecular Devices SpectraMax M5 plate reader.  Results were expressed as a percentage of the control value versus the negative logarithm of the molar drug concentration range using Graph Pad Prism. Relative toxicities of each compound within each cell line were expressed as 50% of growth inhibition (IC50). All determinations were carried out in quadruplicate.
3. RESULTS AND DISCUSSION
3.1 Chemistry
A series of chalcones were prepared in yields of 43-94% by reacting molar equivalents of the appropriate benzaldehyde and acetophenone with ten equivalents of aqueous sodium hydroxide solution in methanol at room temperature (Scheme 1). Recrystalisation from ethanol afforded the desired (E) isomers as yellow crystals. A combinatorial chemistry approach was adopted for these syntheses with no effort being made to optimise individual yields. Analytical data were fully consistent with the proposed structures.
3.2 Antiproliferative activity








Table 1. Antiproliferative activities of chalcones
	











































could easily have been disregarded as being inactive. The antiproliferative activities of the chalcone library were investigated using a human breast cell line panel which has been characterised for CYP expression in our laboratories [8, 9, 10, 11]. This panel consists of MCF-7, an ER positive tumour cell line with very low levels of CYP expression, MCF-7 induced with TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) which expresses high levels of CYP1A1, MDA-MB-468 (MDA-468), an ER negative tumour cell line which constitutively expresses both CYP1B1 and CYP1A1 and MCF-10A, a non-tumour ‘normal’ cell line which has no basal CYP expression. IC50 values were determined using a standard MTT cytotoxicity assay and are shown in Table 1.  
DMU-102 (Entry1, Table1) with a 4-methoxyphenyl B-ring and a 3,4,5 trimethoxyphenyl A-ring showed high antiproliferative activities in the MCF7 and MDA-468 cell lines with IC50 values of 0.06 and 0.07 µM respectively. In the non-tumour MCF-10A cell line a significantly higher IC50 value of 1.5 µM was obtained. When the MCF7 cells were treated with TCDD to induce CYP1A1 expression little change in activity was observed. Although this result indicates that CYP1 activation is not involved in the mechanism of action of this compound it may be the case that this chalcone, like nobiletin, [10] is inducing CYP1 expression in this cell line, thus causing its own bioactivation without the need for TCDD. Changing the trimethoxy substitution on the A-ring to 2,3,4- as in DMU-121 (Entry 2, Table 1) reduced activity in the cancer cell lines. Again, no decrease in IC50 value was seen on treatment of the MCF7 cells with TCDD. With a 2,4-dimethoxy substitution on the A-ring DMU-133 (Entry 3, Table 1) was 10 fold less toxic to the MCF10A cell line than DMU-121 but had a similar IC50 value for the MDA-468 cell line, a 26 fold difference in activities. Perhaps more interesting was the reduction in IC50 value from 8.6 to 0.68 µM on treatment of the MCF7 cell line with TCDD. The higher potency of DMU-133 on induction of CYP1A1 in this cell line suggests that this enzyme may be involved in the prodrug activation of this compound. The 3,5-dimethoxy substituted A-ring derivative DMU-120 (Entry 4, Table 1) was significantly more toxic than DMU-133 to the MCF7 and MCF10A cell lines. Surprisingly, with a 2,5-dimethoxy substitution on the A-ring, DMU-427 was more active in the non CYP expressing cell lines (Entry 5, Table 1), IC50 values increasing from 0.21 µM in the MCF10A cell line to 16.1 µM in the MDA-468 cell line which expresses both CYP1B1 and CYP1A1. Treatment of the MCF7 cells with TCDD to induce CYP1A1 almost doubled the IC50 value for this compound. One possible explanation for these results is that the metabolites produced by these CYPs are less toxic to the cells than the original molecule. The mono substituted A-ring derivative DMU-470 (Entry 6, Table 1) showed relatively little discrimination between the cell lines tested, IC50 values being below 1 µM in each case. Although considerably less toxic DMU-105 with no substituents on the A-ring (Entry 7, Table 1) did show some selectivity for the CYP expressing cells. “Reversing” the aromatic groups in DMU-105 produced a significant decrease in potency to all the cell lines tested DMU-1119 (Entry 8, Table 1) being essentially inactive. A similar reduction in activity was observed with DMU-1113 (Entry 9, Table 1) which is a “reversed analogue” of DMU-102 (Entry 1, Table 1). Based in these results, it is possible to argue that the position of the aromatic groups in relation to the propenone potion of the molecule is an important factor in determining activity. Changing the 4-methoxy group on the B-ring for an ethoxy group was investigated in derivatives DMU-1122 and 5505 (Entries 10 and 11, Table 1). When compared with their respective 4-methoxy analogues (Entries 3 and 1, Table 1) both showed significantly lower toxicities in each of the cell lines tested. It is interesting to note a twofold reduction in IC50 values for both the ethoxy derivatives on treatment of the MCF7 cells with TCDD. Increasing the alkyl chain length from ethoxy to propoxy, as in DMU-408 and DMU-191 (Entries 12 and 13 Table 1), increased activity in the TCDD treated MCF7 cells. This was particularly evident in the 3,4,5-trimethoxy A-ring derivative DMU-191 with an IC50 value of 0.41 µM for these cells. Increasing the chain length further to butyl removed activity completely (Entry 14, Table 1). The effect of adding a second methoxy group at the three position in the B-ring was investigated in analogues DMU-104, 2201 and 2210 (Entries 15, 16 and 17, Table 1). Of these only the 3,4,5-trimethoxy A-ring derivative DMU-104 showed any significant selectivity for the CYP1 expressing cell lines, with IC50 values of 0.5 and 0.95 µM for the MDA-468 and TCDD treated MCF7 cells respectively. Moving the second methoxy group in the B-ring to the two position, as in DMU-132 (Entry 18, Table 1), eliminated the higher activities seen with DMU-104. With a 2,4-dimethoxy substitution on both the A- and B-rings DMU-2207 (Entry 19, Table 1) showed some activity in the MDA-468 cell line with an IC50 of 5 µM while being essentially non-toxic to all the other cells tested. Replacing the 3,4-dimethoxy group in DMU-104 with a methylenedioxy group resulted in a profound increase in activity in the CYP1 expressing cells, DMU-135 (Entry 20, Table 1) having an IC50 of 0.006 µM in MDA-468 cell line and 0.08 µM in the MCF7 cell line after treatment with TCDD. The latter was a 100 fold reduction in IC50 value when compared to the untreated MCF7 cells. In the non-tumour MCF10A cells a comparatively high IC50 of 1.5 µM was obtained. Changing the positions of the three methoxy groups on the A-ring to 2,3,4- as in DMU-419  (Entry 21, Table 1) significantly reduced potency in the CYP1 expressing cell lines compared to DMU-135. The dimethoxy derivative DMU-407 (Entry 23, Table 1) with a 2,4-substitution on the A-ring gave comparable activity to DMU-419, however, the 3,4-dimethoxy substituted B-ring analogue DMU-160 (Entry 23, Table 1) showed relatively little activity in any of the cell lines tested, and no selectivity.  In contrast to DMU-160 the 3,5-dimethoxy substituted derivative DMU-403 (Entry 24, Table 1) was selective for the CYP1 expressing cells, particularly the MDA-468 cell line with an IC50 of 0.14 µM. The 2,5-dimethoxy derivative DMU-423 (Entry 25, Table 1) was also active in this cell line with an IC50 of 0.06 µM but showed greater toxicity towards the non-tumour MCF10A cells. The three monomethoxy substituted A-ring derivatives DMU-2265, 416 and 2267 (Entries 26, 27 and 28, Table 1) were essentially non-toxic to the non-tumour cell line. Of these analogues only DMU-416 showed activity in the cancer cell lines with IC50 values of 8.9 and 6 µM in the MCF7 and MDA-468 cells respectively. DMU-411 (Entry 29, Table 1) with no substituents on the A-ring showed similar activity to DMU-416. Two derivatives were prepared in which the methoxy groups in the A-ring were replaced by chloro groups.  Neither DMU-2219 nor 2263 (Entries 33, and 34, Table 1) showed any significant activity. In light of our earlier findings that the relative positions of the aromatic groups has a significant effect on activity, three analogues of compounds in the 3,4-methylenedioxy B-ring series were prepared in which the aromatic groups had been “reversed.” DMU-1103 and 1144 (Entries 30, and 31, Table 1) were significantly less active in all cell lines than their comparable derivatives DMU-407 and 423 (Entries 22, and 25, Table 1). In contrast DMU-1112 (Entry 32, Table 1) was of comparable activity to DMU-419 (Entry 21, Table 1) in the MCF10A and MDA-468 cell lines but less active in the MCF7 cells.  Treatment of these cells with TCDD resulted in a 100 fold decrease in IC50 value for this compound from 25 to 0.25 µM.  Replacing the 3,4-methylenedioxy group in DMU-407 by an 3,4-(1,2-ethylenedioxy) group, as in DMU-1133, significantly reduced activity in the CYP1 expressing cell lines. As a preliminary investigation into the role played by CYP1 enzymes in the mechanism of action of DMU-135, the cytotoxicity assays for this compound were repeated in the presence of the CYP1 inhibitors acacetin [9, 10, 23] and α-naphthoflavone (NF) [10, 23]. If CYP1 enzymes are involved in the bioactivation of this derivative then their inhibition should result in a decrease in antiproliferative activity. DMU-135 was selected as it shows high activity in the cell lines which express CYP1 enzymes while showing significantly lower toxicity to the MCF10A and MCF7 cell lines where these enzymes are not present. In the MDA-468 cell line which constitutively expresses both CYP1B1 and CYP1A1 a significant reduction in activity was observed on the addition of 1 µM of acacetin, the IC50 for DMU-135 increasing from 0.006 to 0.9 µM (Fig. 2, Graph 1). A similar result was obtained when NF was used in place of acacetin, an IC50 of 1.5 µM being obtained.  In the TCDD treated MCF7 cells which express high levels of CYP1A1 the addition of acacetin increased the IC50 for DMU-135 from 0.08 to 1.5 µM; a similar result was obtained when this assay was repeated using αNF (Fig. 2, Graph 2). In the MCF10A and MCF7 cell lines which have very low levels of CYP1 expression the addition of either acacetin or αNF produced little change in IC50 value for DMU-135 (Fig. 2, Graph 1). Taken together these results provide supporting evidence that DMU-135 is functioning as a CYP1 activated prodrug.
CONCLUSION
	A series of chalcones in yields of 43-94% were synthesized with the Claisen-Schmidt condensation reaction. Of the 4-methoxyphenyl B-ring derivatives prepared DMU-102, with a 3,4,5-trimethoxy substituted A-ring, showed the highest activity in both of the breast cancer cell lines. Significantly lower activity was observed with the non-tumour MCF-10A cells. Treatment of the MCF7 cells with TCDD to induce CYP1A1 expression produced little change in IC50 value for DMU-102 implying that CYP1 activation is not involved in the mechanism of action of this analogue. Alternatively, it may be the case that this chalcone, like nobiletin [10], is self-inducing CYP1 expression in this cell line thus causing its own bioactivation. The 2,4-dimethoxy substituted A-ring derivative DMU-133 although less active in the cancer cell lines than DMU-102 did show an increase in activity on treatment of the MCF7 cells with TCDD, thus indicating prodrug activation by CYP1A1.“Reversing” the aromatic groups in DMU-102 to give DMU-1113 produced a significant decrease in potency suggesting that the positions of the aromatic groups in relation to the propenone potion of the molecule are an important factor in determining activity. With a 3,4-methylenedioxyphenyl group on the B-ring DMU-135 was 10 fold more active than DMU-102 in the MDA-468 cell line but 100 times less active in the MCF7 cells. Induction of CYP1A1 in the MCF7 cell line by treatment with TCDD produced a 100 fold increase in activity for DMU-135 with an IC50 value of 0.08 µM. As with DMU-133 this result suggests prodrug activation by CYP1A1. This is contrary to our previously proposed mechanism of activation for this compound where we postulated CYP1B1 as the key enzyme responsible [22]. The involvement of CYP1 enzymes in the activation of DMU-135 was further supported by the increase in IC50 values seen on addition of the CYP1 inhibitors acacetin and αNF [23] to the MDA-468 and TCDD treated MCF7 cell lines.
	In summary, five chalcones: DMU-133, DMU-191, DMU-135, DMU-403 and DMU-1112 showed significantly higher activity in cell lines which express CYP1A1 and CYP1B1 compared to cells which do not express these enzymes, suggesting that CYP1 activation may be involved in their mechanism of action. Of these derivatives three contained a 3,4-methylenedioxy substitution on one of the rings with the other ring being either di- or trimethoxy substituted.
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